Transformation of 3 current short-acting HIV drugs, Tenofovir, Lamivudine and Dolutegravir (TLD) into a novel, all-in-one long-acting TLD 3-drug-combination in a single injectable dosage that produces extended pharmacokinetics

Conference Reports for NATAP

IAS 2023
July 23rd - 26th
12th IAS Conference on HIV Science


Transformation of 3 current short-acting HIV drugs, Tenofovir, Lamivudine and Dolutegravir (TLD) into a novel, all-in-one long-acting TLD 3-drug-combination in a single injectable dosage that produces extended pharmacokinetics

	IAS 2023 july 24